Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
15.13
+0.18 (1.20%)
Jun 26, 2025, 4:00 PM - Market closed
Travere Therapeutics Revenue
Travere Therapeutics had revenue of $81.73M in the quarter ending March 31, 2025, with 97.54% growth. This brings the company's revenue in the last twelve months to $273.53M, up 75.65% year-over-year. In the year 2024, Travere Therapeutics had annual revenue of $233.18M with 60.55% growth.
Revenue (ttm)
$273.53M
Revenue Growth
+75.65%
P/S Ratio
4.52
Revenue / Employee
$710,475
Employees
385
Market Cap
1.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 233.18M | 87.94M | 60.55% |
| Dec 31, 2023 | 145.24M | 35.78M | 32.69% |
| Dec 31, 2022 | 109.46M | -22.38M | -16.97% |
| Dec 31, 2021 | 131.84M | -66.49M | -33.52% |
| Dec 31, 2020 | 198.32M | 22.98M | 13.11% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
TVTX News
- 14 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 16 days ago - Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference - Business Wire
- 17 days ago - Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day - Business Wire
- 22 days ago - Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 23 days ago - Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress - Business Wire
- 23 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation - Accesswire
- 24 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect - Accesswire
- 25 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach Out - Accesswire